Quince Therapeutics (QNCX) vs TransCode Therapeutics (RNAZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
TransCode Therapeutics (RNAZ) has outperformed Quince Therapeutics (QNCX) over the past year, losing 88.4% versus a loss of 92.4%. Over five years, QNCX leads with a -99.8% price change compared with -100.0% for RNAZ. Quince Therapeutics is the larger company by market cap ($29.9 million vs $29.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QNCX | RNAZ |
|---|---|---|
| Share price | $29.36 | $1.71 |
| Market cap | $29.86M | $28.95M |
| 1-day change | +9.88% | -2.84% |
| YTD return | -95.62% | -74.96% |
| 1-year return | -92.35% | -88.45% |
| 5-year return | -99.77% | -100.00% |
| EPS (TTM) | $-214.01 | $-52.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $910.00 | $15.94 |
| 52-week low | $15.10 | $1.52 |
| Distance from 52-week high | -96.77% | -89.27% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +156.91% | — |
| Average volume | 28.83K | 50.19K |
| Shares outstanding | 1.02M | 16.93M |
| Employees | 38 | 12 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Quince Therapeutics
QNCX stock →Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Healthcare · Biotechnology · 38 employees
About TransCode Therapeutics
RNAZ stock →TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.
Healthcare · Biotechnology · 12 employees
QNCX vs RNAZ FAQ
Which is bigger, Quince Therapeutics or TransCode Therapeutics?
Quince Therapeutics (QNCX) is larger, with a market capitalization of $29.86M compared with $28.95M for TransCode Therapeutics (RNAZ).
Which stock has performed better over the past year, QNCX or RNAZ?
RNAZ returned -88.45% over the past 12 months, compared with -92.35% for QNCX (price return, excluding dividends). Past performance does not predict future results.
Are Quince Therapeutics and TransCode Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.